Home > Healthcare > Medical Devices > Therapeutic Devices > xenotransplantation market
Get a free sample of Xenotransplantation Market
Your inquiry has been received. Our team will reach out to you with the required details via email. To ensure that you don't miss their response, kindly remember to check your spam folder as well!
Form submitted successfully!
Error submitting form. Please try again.
Get a free sample of Xenotransplantation Market
Your inquiry has been received. Our team will reach out to you with the required details via email. To ensure that you don't miss their response, kindly remember to check your spam folder as well!
Form submitted successfully!
Error submitting form. Please try again.
Advancements in organ preservation technologies, including machine perfusion and cryopreservation methods, enhance the viability and quality of xenogeneic organs.Similarly, advances in genetic engineering techniques, such as CRISPR-Cas9 allows healthcare professionals to modify animal genomes to create genetically engineered pigs or other animals with organs that are more compatible with human recipients. Further, increasing adoption of robotics in minimally invasive surgical techniques will provide potential to improve the precision and safety of xenotransplantation procedures. Robotic-assisted surgery can enhance surgical outcomes and reduce post-operative complications.
Novartis AG, Immerge BioTherapeutics, Inc., United Therapeutics Corporation, Infigen, Inc., eGenesis, Inc., NZeno Limited, Preservation Solutions, Inc., Xeno Transplants Corporation, F. Hoffmann-La Roche Ltd. and OrganOX Limited among others.
U.S. market accounted for USD 7 billion in 2022 and will witness considerable market growth during 2023-2032, attributed to the growing prevalence of chronic diseases such as end-stage renal disease, heart failure, and liver failure in the region.
The transplant diagnostics segment garnered over USD 5.4 billion in 2022 owing to the growing chronic diseases burden worldwide that leads to surge in the number of organ failure cases.
Global market for xenotransplantation was valued at USD 12.7 billion in 2022 and is estimated to account for USD 29.9 billion by 2032, backed by the ongoing R&D in genetic engineering, immunosuppressive therapies, and organ preservation technologies.